[Beacon Staff]

ASH 2015 multiple myeloma abstracts

by Beacon Staff on Wed Dec 09, 2015 12:52 pm

Hi everyone,

The full text of more than 500 myeloma-related abstracts from this year's American Society of Hematology (ASH) meeting are now available here at The Beacon. This link will take you to a list of the abstracts:

https://myelomabeacon.org/resources/mtgs/ash2015/abs/

Clicking on the title of an abstract will bring up the full text of the abstract.

Note that the abstracts can be searched in a number of ways (by title, by text in the abstract, by abstract type, etc.) Just keep in mind that if you are looking for abstracts about a particular drug, you should use the drug's generic name (lenalidomide, for example, instead of Revlimid) when doing the search. We have included at the end of this post a list of generic and brand names for common myeloma-related therapies.

Abstracts also will be receiving tags that will make it easier to find all abstracts about, for example, stem cell transplantation. The tagging process, however, takes a while.

Note that the only way to search for abstracts is through the search box at the top of each abstract, meeting-related tag pages, and the overall list of ASH 2015 abstracts. The general search box for the Beacon does not bring up ASH 2015 abstracts.

Commenting on the abstracts is permitted and encouraged. You can ask questions, as well, but please keep in mind that the questions most likely will have to be answered by other Beacon readers. We generally won't be responding to questions related to the abstracts.

As with past meetings, we also will be adding full slide decks and posters for the abstracts, courtesy of the abstract authors. You can find one of the those slide decks already accompanying the abstract for the presentation given by Beacon Medical Advisor Dr. Ken Shain on "Mathematical Models of Cancer Evolution and Cure". (If you're interested in clonal evolution in multiple myeloma, you should check out Dr. Shain's presentation.)

Of course, we'll also be publishing a series of articles about this year's meeting. We think the articles will be particularly valuable this year to help highlight what was important at the meeting, and also to sort through some of the hype and promotion that has gone related to presentations at the meeting.

Selected Myeloma-Related Therapies - Generic & Brand Names

lenalidomide Revlimid
thalidomide Thalomid
pomalidomide Pomalyst, Imnovid

bortezomib Velcade
carfilzomib Kyprolis
ixazomib Ninlaro

panobinostat Farydak

daratumumab Darzalex
elotuzumab Empliciti

cyclophosphamide Cytoxan

pamidronate Aredia
zoledronic acid Zometa

[Multibilly]

Re: ASH 2015 multiple myeloma abstracts

by Multibilly on Thu Dec 10, 2015 9:06 am

Many thanks for pulling all these together Beacon staff!! You guys are such a great resource and we appreciate all the effort you put into this site.

[Nancy Shamanna]

Re: ASH 2015 multiple myeloma abstracts

by Nancy Shamanna on Thu Dec 10, 2015 9:22 am

Thanks very much Beacon Staff! I will look for abstracts too, of interest! I by now know some of the scientists who publish poster presentations and give talks there, so it is interesting for me to follow also.

[Boris Simkovich]

Re: ASH 2015 multiple myeloma abstracts

by Boris Simkovich on Mon Dec 14, 2015 1:18 pm

Thanks, Multibilly and Nancy, for your feedback.

As you and others here may have noticed, we've been adding PDF files with complete slide decks and posters to the database of ASH abstracts. A running list of abstracts to which we've added links to the related slide decks or full posters is in the Beacon's sidebar on the right, under "ASH 2015 Abstracts - Recent Updates".

We've also recently uploaded to our server a presentation that was given by Dr. Saad Usmani at one of the "satellite symposia" that occurred prior to the official start of ASH. The presentation summarizes data on various treatment options for relapsed myeloma; it can be viewed here:

S Usmani, "Updates on Options for Relapsed/Refractory Disease" (ASH 2015 satellite symposium presentation)

[Nancy Shamanna]

Re: ASH 2015 multiple myeloma abstracts

by Nancy Shamanna on Mon Dec 14, 2015 4:40 pm

Thanks Boris, I read the above posted summary by Dr. Usmani about the Tourmaline, Eloquent 2 and Aspire studies. In each study hundreds of patients were randomized into two groups. The first group would be receiving the new drug plus Len/Dex, and the second group just Len/Dex. I found it interesting that in each case the control group was on the same treatment of Rev/Dex. The dex was at 40 mg./week, which is a strong dosage. In each study the new drug produced a greater PFS than with the Len/Dex alone. If patients were resistant to IMID's, Kyprolis or Elotuzumab were not really effective, and elotuzumab was effective for 'high risk' patients as described by chromosomal testing. This was a useful summary of the newer drugs!

[Ron Harvot]

Re: ASH 2015 multiple myeloma abstracts

by Ron Harvot on Mon Dec 14, 2015 6:55 pm

The studies that really impressed me are two that evaluated Daratumumab in relapsed and refractory patients. With the addition of Revlimid and Dex one of the studies showed that 88% of the parients responded and that the response deepened over time. After 19 months the medium duration of response had not yet been met!!

This is a game changer in my opinion.